Loading...

Allergy Therapeutics plc

AGY.LLSE
HealthcareDrug Manufacturers - Specialty & Generic
£6.80
£-0.60(-8.11%)

Allergy Therapeutics plc (AGY.L) Company Profile & Overview

Explore Allergy Therapeutics plc’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Allergy Therapeutics plc (AGY.L) Company Profile & Overview

Allergy Therapeutics plc, a biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex Quattro, Oralvac, Venomil, ImmunoBON, Synbiotics, Acarovac Plus, Penicillin diagnostics, Pollinex, and VLP Peanut. The company also develops allergy vaccines for trees, grass, house dust mite, and pets with fur/hair, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CEOMr. Manuel Llobet

Contact Information

44 1903 844 700
Dominion Way, Worthing, BN14 8SA

Company Facts

612 Employees
IPO DateOct 11, 2004
CountryGB
Actively Trading

Frequently Asked Questions